Zealand Pharma A/S (ZLDPF) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Core Insights - Zealand Pharma has had an exciting year, highlighted by a significant partnership with Roche, which was established in March and has progressed rapidly towards Phase III for the petrelintide asset [3]. Company Overview - David Kendall has been with Zealand Pharma for 5 years and serves as the Chief Medical Officer, bringing prior experience from Eli Lilly and Amylin Pharmaceuticals [2]. Partnership Highlights - The partnership with Roche is a focal point for Zealand Pharma, with rapid advancements in their metabolism portfolio and the petrelintide asset [3].